Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155167 | 0.83 | HRH3 (0.42) | PDK1 | |
| SCHEMBL2551511 | 0.79 | MLYCD (0.38) | ALDH1A1MEN1KMT2APOLBRAB9A | |
| SCHEMBL1241389 | 0.77 | LSS (0.40) | ALDH1A1MEN1KMT2APOLBRAB9A | |
| SCHEMBL2376808 | 0.76 | CD274 (0.42) | ALDH1A1MEN1KMT2A | |
| SCHEMBL2552511 | 0.76 | TSHR (0.41) | L3MBTL1ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL5065542 | 0.76 | PDK1 (0.43) | PDK1ATMHTR1AMEN1KMT2A | |
| SCHEMBL1242387 | 0.75 | NPC1 (0.40) | L3MBTL1ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL3298782 | 0.74 | HTR1A (0.36) | SIGMAR1HTR1ARAB9A | |
| SCHEMBL2929114 | 0.73 | MLYCD (0.38) | MEN1KMT2ARAB9A | |
| SCHEMBL21871203 | 0.73 | SIGMAR1 (0.45) | SIGMAR1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217032-B2 | Selective estrogen receptor modulators for the treatment of vasomotor symptoms | ELI LILLY AND COMPANY (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217032-B2 | Selective estrogen receptor modulators for the treatment of vasomotor symptoms | ELI LILLY AND COMPANY (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217032-B2 | Selective estrogen receptor modulators for the treatment of vasomotor symptoms | ELI LILLY AND COMPANY (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110281847-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281847-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281847-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2011-11-17 | — | — | US | disclosed |
| EP-1709021-B1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | LILLY CO ELI (US) | 2010-08-04 | — | — | EP | disclosed |
| US-20090023917-A1 | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023917-A1 | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023917-A1 | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1709021-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073204-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023917-A1 | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms | GPER1, ESR1, HSD17B11 | SIGMAR1 441/4885PDK1 3232/4885ATM 3733/4885 |
| US-20110281847-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | GPER1, ESR1, HSD17B11 | SIGMAR1 441/4885PDK1 3232/4885ATM 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.